Pliant Therapeutics (PLRX)
(Delayed Data from NSDQ)
$13.65 USD
+2.05 (17.67%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.63 -0.02 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
PLRX 13.65 +2.05(17.67%)
Will PLRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PLRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PLRX
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
PLRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Other News for PLRX
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Pliant Therapeutics (PLRX) Gets a Buy from Piper Sandler
Bullish on Bexo: Pliant Therapeutics’ Promising IPF Treatment Backed by Strong Clinical Evidence